Click here to learn about Academy events, publications and initiatives around COVID-19.

We are experiencing intermittent technical difficulties. At this time, you may not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Our site is under planned maintenance. At this time, you will not be able to log in, register for an event, or make a donation via the website. We appreciate your patience, and apologize for any inconvenience this may cause.

Support The World's Smartest Network

Help the New York Academy of Sciences bring late-breaking scientific information about the COVID-19 pandemic to global audiences. Please make a tax-deductible gift today.

This site uses cookies.
Learn more.


This website uses cookies. Some of the cookies we use are essential for parts of the website to operate while others offer you a better browsing experience. You give us your permission to use cookies, by continuing to use our website after you have received the cookie notification. To find out more about cookies on this website and how to change your cookie settings, see our Privacy policy and Terms of Use.

We encourage you to learn more about cookies on our site in our Privacy policy and Terms of Use.

Pulmonary Hypertension: Beyond Vasodilators



Pulmonary Hypertension: Beyond Vasodilators

Tuesday, October 12, 2021, 11:00 AM - 5:00 PM EDT


Presented By

Biological Pharmacological Discussion Group

The New York Academy of Sciences


Pulmonary hypertension (PH) is a highly morbid condition without cure. Some forms of PH, such as Pulmonary Arterial Hypertension (PAH) have a mean survival of 5-years after diagnosis with mortality most commonly due to right heart failure. Current therapies include several classes of vasodilators, including prostacyclins, calcium channel blockers, PDE5 inhibitors, endothelin receptor antagonists (ETRA), and soluble guanylate cyclase stimulators, all of which are limited by systemic hypotension. Several agents including ETRA and prostacyclin have additional dose-limiting systemic side effects or toxicities. Moreover, many patients are unresponsive to these agents at diagnosis or during the course of therapy, due to advanced disease, progression, or drug tachyphylaxis. Given these limitations, there is a strong need for new therapies beyond vasodilators acting by novel anti-proliferative, anti­fibrotic, or anti-inflammatory mechanisms to modify the natural history of disease. This virtual symposium will convene basic researchers, clinicians, and drug developers to discuss latest advances in the development of novel therapeutics that can overcome the limitations of current therapy for PH.


Nonmember Academia, Faculty, etc.
Nonmember Corporate, Other
Nonmember Not for Profit
Nonmember Student, Undergrad, Grad, Fellow
Member Student, Post-Doc, Fellow

Scientific Organizing Committee

Yinglin Gao, PhD

Regeneron Pharmaceuticals

Elena A. Goncharova, PhD

University of California Davis

Scott MacDonnell, PhD

Regeneron Pharmaceuticals

Paul B. Yu, MD, PhD

Harvard Medical School, Brigham and Women's Hospital

Sonya Dougal, PhD

The New York Academy of Sciences

Barbara Knappmeyer, PhD

The New York Academy of Sciences

Program Supporters


October 12, 2021

11:00 AM

Welcome Remarks


Barbara Knappmeyer, PhD
The New York Academy of Sciences
11:10 AM

Conference Overview


Scientific Organizing Committee

Session 1: Vessel Remodeling: Molecular Mechanisms and Therapeutic Targets

Session Chairperson
Elena A. Goncharova, PhD
11:20 AM

Epigenetic Landscape of Pulmonary Hypertension: Emerging Therapeutic Avenue


Soni S. Pullamsetti, PhD
Max Planck Institute for Heart and Lung Research
11:50 AM

Ion Channels as Drug Targets for Pulmonary Hypertension


Jason Yuan, PhD
The University of California San Diego
12:20 PM

Presentation To Be Announced

Session 2: Short Talks and Poster Session

12:50 PM

Networking Lunch Break with Virtual Poster Session

1:50 PM

Short Talk 1 (Selected from Abstract Submissions)

2:05 PM

Short Talk 2 (Selected from Abstract Submissions)

2:20 PM

Short Talk 3 (Selected from Abstract Submissions)

Session 3: Emerging Therapies for Right Ventricular Dysfunction and Failure

2:35 PM

Pathways Regulating Right Ventricular Adaptation vs Decompensation


Naomi C. Chesler, PhD
University of California, Irvine
3:05 PM

Novel Therapeutic Strategies to Promote Right Ventricular Adaptation in Pulmonary Hypertension


Tim Lahm, MD
Indiana University School of Medicine
3:35 PM

The Right Heart as Therapeutic Target in Pulmonary Hypertension


Frances de Man, PhD
VU University Medical Center, Amsterdam
4:05 PM


Session 4: Pulmonary Hypertension Beyond Vasodilation: Clinical Practice

4:20 PM

Signaling Through the Receptors of the TGF-β Family: Impact on Vascular Remodeling and Cardiac Effects in PAH


Paul Yu, MD, PhD
Brigham and Women's Hospital, Harvard Medical School
4:50 PM

Targeting TGFb/BMP Signaling with Sotatercept (ACE-011)


Janethe Deolina Oliveira Pena, MD, PhD
Acceleron Pharma
5:20 PM

Closing Remark


Barbara Knappmeyer, PhD
The New York Academy of Sciences
5:25 PM

Conference Ends